title: Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
abstract: To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, open-label, randomized, controlled study. Twenty-one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no-treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration.
authors.affiliation: Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy. m.detommaso@neurol.uniba.it
authors.forename: Marina
authors.initials: M
authors.lastname: de Tommaso
authors.forename: Nicola
authors.initials: N
authors.lastname: Specchio
authors.forename: Vittorio
authors.initials: V
authors.lastname: Sciruicchio
authors.forename: Olimpia
authors.initials: O
authors.lastname: Difruscolo
authors.forename: Luigi Maria
authors.initials: LM
authors.lastname: Specchio
mesh_terms: D000328:Adult; D000368:Aged; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D003710:Demography; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D011446:Prospective Studies; D000068836:Rivastigmine; D012720:Severity of Illness Index; D019680:Trinucleotide Repeat Expansion / Q000235:genetics
chemical_list: D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine